Zacks Investment Research upgraded shares of Aquestive Therapeutics (NASDAQ:AQST – Get Rating) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.
According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “
AQST has been the subject of a number of other reports. Wedbush dropped their price objective on Aquestive Therapeutics from $26.00 to $8.00 and set an outperform rating for the company in a report on Thursday, March 10th. HC Wainwright restated a buy rating and set a $14.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, December 23rd.
Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). The business had revenue of $11.08 million during the quarter, compared to the consensus estimate of $9.81 million. During the same period in the previous year, the business earned ($0.60) EPS. As a group, research analysts anticipate that Aquestive Therapeutics will post -1.64 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Jump Financial LLC boosted its position in Aquestive Therapeutics by 62.3% in the 3rd quarter. Jump Financial LLC now owns 49,700 shares of the company’s stock valued at $216,000 after buying an additional 19,070 shares during the last quarter. Balyasny Asset Management LLC bought a new position in shares of Aquestive Therapeutics during the third quarter worth about $646,000. IndexIQ Advisors LLC lifted its position in shares of Aquestive Therapeutics by 11.1% during the third quarter. IndexIQ Advisors LLC now owns 86,461 shares of the company’s stock worth $377,000 after purchasing an additional 8,660 shares during the last quarter. GSA Capital Partners LLP lifted its position in shares of Aquestive Therapeutics by 203.9% during the third quarter. GSA Capital Partners LLP now owns 297,229 shares of the company’s stock worth $1,296,000 after purchasing an additional 199,428 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Aquestive Therapeutics by 381.3% during the fourth quarter. Bank of America Corp DE now owns 36,371 shares of the company’s stock worth $141,000 after purchasing an additional 28,814 shares during the last quarter. 39.17% of the stock is owned by hedge funds and other institutional investors.
Aquestive Therapeutics Company Profile (Get Rating)
Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
- Get a free copy of the StockNews.com research report on Aquestive Therapeutics (AQST)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.